FDA staff worry about risks of cancer, suicide in COPD drug Daxas

04/5/2010 | Reuters

FDA reviewers voiced concern about suicide and suicide attempts by clinical-trial patients who received Daxas, a drug for chronic obstructive pulmonary disease from Forest Laboratories and Nycomed. Forest said an analysis of the cases "does not suggest a causal relationship" with Daxas, which is also linked to a higher risk of cancer, according to FDA data.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ